Microba Life Sciences (ASX:MAP) ROE % Adjusted to Book Value: -44.32% (As of Dec. 2025)


What is Microba Life Sciences ROE % Adjusted to Book Value?

Microba Life Sciences ASX:MAP +2.56% ROE % Adjusted to Book Value is -44.32% as of Dec. 2025. The stock has 6 warning signs investors should review.

Microba Life Sciences's ROE % for the quarter that ended in Dec. 2025 was -67.37%. Microba Life Sciences's PB Ratio for the quarter that ended in Dec. 2025 was 1.52. Microba Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -44.32%.

Microba Life Sciences ROE % Adjusted to Book Value Related Terms

Microba Life Sciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences ROE % Adjusted to Book Value Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
-20.85 -13.17 -28.72 -30.03

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only -31.90 -21.47 -12.24 -39.97 -44.32

ASX:MAP vs TMO, DHR, IDXX: ROE % Adjusted to Book Value Comparison

For the Diagnostics & Research subindustry, Microba Life Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microba Life Sciences ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Microba Life Sciences's ROE % Adjusted to Book Value falls into.


Microba Life Sciences ROE % Adjusted to Book Value Calculation

Microba Life Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-40.54% / 1.35
=-30.03%

Microba Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-67.37% / 1.52
=-44.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -44.32% mean?
Microba Life Sciences (ASX:MAP) has a ROE % Adjusted to Book Value of -44.32% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Microba Life Sciences and its competitors.
Is Microba Life Sciences' ROE % Adjusted to Book Value too high?
Microba Life Sciences' current ROE % Adjusted to Book Value is -44.32%.
How does Microba Life Sciences' ROE % Adjusted to Book Value compare to TMO and DHR?
Microba Life Sciences' ROE % Adjusted to Book Value of -44.32% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current ROE % Adjusted to Book Value is -44.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84% below its estimated fair value. The current ROE % Adjusted to Book Value is -44.32%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current ROE % Adjusted to Book Value is -44.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.